Coya Therapeutics

Q2 FY2026 EarningsQ2 FY26 performance beat consensus expectations across top and bottom lines. Revenue reached $243.7K vs. $104.3K expected, primarily driven by R&D collaboration milestones. GAAP EPS of -$0.28 significantly outperformed the -$0.35 consensus, aided by disciplined G&A spending and a larger share base. With $43.2M in cash, the company maintains a runway into H2 2027, covering the critical ALSTARS Phase 2 topline data readout in Q1 2027.